|Bid||6.31 x 100|
|Ask||6.34 x 500|
|Day's Range||6.25 - 6.35|
|52 Week Range||4.40 - 7.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biotech company MediciNova Inc. said late Thursday that it had received positive top-line results from the company's clinical trial of MN-166 in amyotrophic lateral sclerosis. Shares went on a rampage ...
MediciNova Inc (NASDAQ:MNOV), a USD$251.26M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoingRead More...
MediciNova Inc (NASDAQ:MNOV), a biotechnology company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqGM. As aRead More...
On June 5, 2017, MediciNova (MNOV) announced that Professor Kerrie McDonald presented results from a preclinical study of MN-166 (ibudilast) in the treatment of glioblastoma (GBM) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Proteomic profiling of samples from 30 GBM patients revealed macrophage inhibitory factor (MIF) as a protein that was expressed in “poor responders” (e.g., those that lived
There have been a number of recent announcements regarding MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS), which is a rapidly progressing neurodegenerative disease whereby the nerve cells in the brain and spinal cord that control muscle movement degenerate. - On February 7, 2017, MediciNova, Inc. (MNOV) announced that an abstract regarding the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) will be presented at the American Academy of Neurology (AAN) 69th Annual Meeting, which is taking place from Apr. 22-28, 2017 in Boston, Massachusetts. - On December 20, 2016, MediciNova announced that the European Commission has granted Orphan Medicinal Product Designation (OMPD) for MN-166 for the treatment of ALS.
On December 19, 2016, MediciNova, Inc. (MNOV) announced that the Data and Safety Monitoring Board (DSMB) for the ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS) reviewed the results of the interim efficacy analysis and recommended to the National Institute of Neurological Diseases and Stroke (NINDS) that the trial should continue as planned, to which the NINDS has agreed. Thus, the fact that the DSMB recommended that the trial continue as planned is indicative that there is at least a positive trend in the direction of efficacy for MN-166. If there was no trend in favor of MN-166, the trial would have been stopped for futility.
Categories: Yahoo Finance Get free summary analysis MediciNova, Inc. reports financial results for the quarter ended September 30, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -2.84 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. MNOV-US‘s earnings and ... Read more (Read more...)